» Articles » PMID: 9864015

Acute Effects of Inhaled Nitric Oxide in Adult Respiratory Distress Syndrome

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 1998 Dec 24
PMID 9864015
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

This study evaluated the dose-response effect of inhaled nitric oxide (NO) on gas exchange, haemodynamics, and respiratory mechanics in patients with adult respiratory distress syndrome (ARDS). Of 19 consecutive ARDS patients on mechanical ventilation, eight (42%) responded to a test of 10 parts per million (ppm) NO inhalation with a 25% increase in arterial oxygen tension (Pa,O2,) over the baseline value. The eight NO-responders were extensively studied during administration of seven inhaled NO doses: 0.5, 1, 5, 10, 20, 50 and 100 ppm. Pulmonary pressure and pulmonary vascular resistance exhibited a dose-dependent decrease at NO doses of 0.5-5 ppm, with a plateau at higher doses. At all doses, inhaled NO improved O2 exchange via a reduction in venous admixture. On average, the increase in Pa,O2, was maximal at 5 ppm NO. Some patients, however, exhibited maximal improvement in Pa,O2 at 100 ppm NO. In all patients, the increase in arterial O2 content was maximal at 5 ppm NO. The lack of further increase in arterial O2 content above 5 ppm partly depended on an NO-induced increase in methaemoglobin. Respiratory mechanics were not affected by NO inhalation. In conclusion, NO doses < or =5 ppm are effective for optimal treatment both of hypoxaemia and of pulmonary hypertension in adult respiratory distress syndrome. Although NO doses as high as 100 ppm may further increase arterial oxygen tension, this effect may not lead to an improvement in arterial O2 content, due to the NO-induced increase in methaemoglobin. It is important to consider the effect of NO not only on arterial oxygen tension, but also on arterial O2 content for correct management of inhaled nitric oxide therapy.

Citing Articles

High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II Trial.

Di Fenza R, Shetty N, Gianni S, Parcha V, Giammatteo V, Safaee Fakhr B Am J Respir Crit Care Med. 2023; 208(12):1293-1304.

PMID: 37774011 PMC: 10765403. DOI: 10.1164/rccm.202304-0637OC.


Inhaled Nitric Oxide in Acute Respiratory Distress Syndrome Subsets: Rationale and Clinical Applications.

Redaelli S, Pozzi M, Giani M, Magliocca A, Fumagalli R, Foti G J Aerosol Med Pulm Drug Deliv. 2023; 36(3):112-126.

PMID: 37083488 PMC: 10402704. DOI: 10.1089/jamp.2022.0058.


Right ventricle-specific therapies in acute respiratory distress syndrome: a scoping review.

Ganeriwal S, Alves Dos Anjos G, Schleicher M, Hockstein M, Tonelli A, Duggal A Crit Care. 2023; 27(1):104.

PMID: 36907888 PMC: 10008150. DOI: 10.1186/s13054-023-04395-9.


Inhaled nitric oxide: role in the pathophysiology of cardio-cerebrovascular and respiratory diseases.

Signori D, Magliocca A, Hayashida K, Graw J, Malhotra R, Bellani G Intensive Care Med Exp. 2022; 10(1):28.

PMID: 35754072 PMC: 9234017. DOI: 10.1186/s40635-022-00455-6.